COLAROSSI, SABRINA
 Distribuzione geografica
Continente #
NA - Nord America 1.701
AS - Asia 1.196
EU - Europa 1.018
AF - Africa 82
SA - Sud America 72
Continente sconosciuto - Info sul continente non disponibili 64
OC - Oceania 1
Totale 4.134
Nazione #
US - Stati Uniti d'America 1.649
SG - Singapore 307
CN - Cina 306
GB - Regno Unito 260
VN - Vietnam 260
SE - Svezia 174
IT - Italia 126
DE - Germania 99
JP - Giappone 85
HK - Hong Kong 74
FR - Francia 61
IN - India 55
UA - Ucraina 54
NL - Olanda 51
BR - Brasile 46
RU - Federazione Russa 39
IE - Irlanda 37
CA - Canada 29
TG - Togo 25
KR - Corea 23
CI - Costa d'Avorio 22
FI - Finlandia 22
ZA - Sudafrica 21
JO - Giordania 20
BG - Bulgaria 19
GR - Grecia 15
EE - Estonia 14
BE - Belgio 12
CH - Svizzera 12
AR - Argentina 11
PL - Polonia 10
PH - Filippine 9
BD - Bangladesh 8
SC - Seychelles 7
IR - Iran 6
EC - Ecuador 5
ES - Italia 5
ID - Indonesia 5
IQ - Iraq 5
MX - Messico 5
NG - Nigeria 5
SA - Arabia Saudita 5
CL - Cile 4
CR - Costa Rica 4
JM - Giamaica 4
PK - Pakistan 4
TR - Turchia 4
AT - Austria 3
TH - Thailandia 3
TW - Taiwan 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
EG - Egitto 2
GT - Guatemala 2
HN - Honduras 2
LB - Libano 2
NI - Nicaragua 2
PA - Panama 2
PE - Perù 2
PY - Paraguay 2
VE - Venezuela 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CY - Cipro 1
CZ - Repubblica Ceca 1
IL - Israele 1
KG - Kirghizistan 1
LT - Lituania 1
MN - Mongolia 1
MT - Malta 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SX - ???statistics.table.value.countryCode.SX??? 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.072
Città #
Southend 227
Singapore 224
Chandler 215
Ashburn 150
Fairfield 123
San Jose 81
Tokyo 76
Hong Kong 70
Houston 66
Woodbridge 58
Hefei 57
Ho Chi Minh City 56
Wilmington 56
New York 50
Cambridge 49
Seattle 49
Santa Clara 48
Princeton 46
Hanoi 43
Ann Arbor 41
Beijing 39
Jacksonville 38
Dublin 37
Dallas 33
Council Bluffs 32
Boardman 29
Lomé 25
Turin 23
Abidjan 22
Westminster 22
Helsinki 21
Amman 20
Nanjing 19
Sofia 19
Seoul 18
Lauterbourg 17
Padova 17
Da Nang 14
Phoenix 13
Brussels 12
Buffalo 12
Chicago 12
Los Angeles 12
Toronto 11
Bern 10
Medford 10
Nanchang 10
Orem 10
Warsaw 10
Haiphong 9
Jinan 9
Saint Petersburg 9
San Diego 9
Shenyang 9
Falkenstein 8
Florence 8
Bologna 7
Haikou 7
Milan 7
Montreal 7
São Paulo 7
Bengaluru 6
Changsha 6
Guangzhou 6
Hangzhou 6
Munich 6
Shanghai 6
Tianjin 6
Atlanta 5
Berlin 5
Brooklyn 5
Frankfurt am Main 5
Hebei 5
Mahé 5
Taizhou 5
Abbeville 4
Baghdad 4
Can Tho 4
Chiyoda-ku 4
Jiaxing 4
Johannesburg 4
Olalla 4
Redmond 4
Zhengzhou 4
Abeokuta 3
Amsterdam 3
Andover 3
Bexley 3
Bremen 3
Chandigarh 3
Des Moines 3
Grafing 3
Ha Long 3
Hamamatsu 3
Istanbul 3
Mexico City 3
Mountain View 3
Mülheim 3
Ninh Bình 3
Qingdao 3
Totale 2.609
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 368
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 333
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 319
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 278
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 221
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 219
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. 207
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 205
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 201
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 195
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 179
Ultra-Deep Sequencing (UDS) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 177
Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders. 176
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 175
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 175
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP) 140
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 134
New drugs to overcome meccanisms of resistance in Ph+ leukemia: Bosutinib 133
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis 110
null 104
null 85
Totale 4.134
Categoria #
all - tutte 10.478
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.478


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022372 0 0 0 48 40 32 8 18 26 26 76 98
2022/2023624 83 130 23 77 37 49 14 30 98 12 57 14
2023/2024227 5 22 6 12 17 105 25 9 5 3 12 6
2024/2025452 12 67 33 33 59 35 18 19 2 63 26 85
2025/20261.056 85 82 109 57 172 56 87 35 202 108 36 27
2026/2027262 28 53 106 75 0 0 0 0 0 0 0 0
Totale 4.134